2017 Kicks Off with New Treatments for Pediatric Neuromuscular Disorders

The last week of December 2016 finds us with the first and second ever FDA-approved treatments for two groups of affected individuals with Duchenne (DMD) and spinal muscular atrophy (SMA). This long- awaited news arrives just in time to wrap up a year of milestone achievements which began August 30th with the Santhera Pharmaceuticals press release announcing the FDA grant to conduct a Phase 1 Study of Omigapil (CALLISTO) for the treatment of Congenital Muscular Dystrophy (CMD). These achievements were the product of a large team effort that starts with YOU, the affected individuals, families and caregivers, as the core of this team. You are surrounded by tenacious players: advocacy groups li

Adapted Vehicles and Driving

Vehicles and Conversions The privilege for any disabled person is to obtain their driver's license and drive a vehicle. Driving can give a sense of independence that is greater then one can ever imagine. It can give the person an opportunity to essentially blend in with society and become like any other driver on the road. The actual process of not only the evaluation, lessons, and testing, but also the process of acquiring a vehicle suited to the driver can be extremely difficult. Despite this, the freedom and independence gained from all this effort justifies this tough process. While the process can vary from state to state, the following article should provide a general overview of the p

Connect with Us

Cure CMD

3217 E. Carson St. #1014
Lakewood, CA 90712 USA


General Inquiries:


Research Grants:

About Us

Copyright © 2020 Cure CMD

Cure CMD is U.S. registered 501(c)(3) non-profit organization. Donations are tax deductible to the
extent allowable by law.  U.S. Federal Tax ID: 26-2640975